AI Article Synopsis
- The study focuses on patients with malignant lung cancer who develop new lung nodules post-treatment, making it hard to differentiate between new primary lung cancer and metastases.
- Researchers reviewed records of 10 patients who received stereotactic body radiation therapy (SBRT) combined with chemotherapy from 2007 to 2013, delivering a total dose of 48 Gy.
- Results showed a 90% complete response rate, indicating the treatment was effective and had a safety profile comparable to traditional chemoradiotherapy.
Article Abstract
Background/aim: Patients with malignant lung cancer often develop a solitary pulmonary nodule after treatment of the initial cancer. In those cases, it is difficult to distinguish primary lung cancer (PLC) from lung metastasis. Therefore, both local therapy for a single lung lesions and systemic therapy for micrometastases are needed. This retrospective study aimed to evaluate the safety and tolerability of concurrent stereotactic body radiation therapy (SBRT) and chemotherapy in patients with metachronous PLC.
Patients And Methods: We reviewed the records of 10 patients with metachronous PLC treated with SBRT and concurrent chemotherapy with curative intent from 2007 to 2013. The delivered radiation dose was 48 Gy in four fractions.
Results: All patients received SBRT with concurrent chemotherapy on schedule. Complete response rate was 90%. Safety profile of this treatment was compatible with that of traditional chemoradiotherapy.
Conclusion: Our study showed good feasibility and safety for SBRT with concurrent chemoradiotherapy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!